1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. DBV Technologies
  6. Summary
    DBV   FR0010417345

DBV TECHNOLOGIES

(DBV)
  Report
Real-time Euronext Paris  -  03:30 2022-08-19 am EDT
4.926 EUR   +0.37%
08/18European ADRs Move Lower in Thursday Trading
MT
08/12European ADRs Move Slightly Lower in Friday Trading
MT
08/10European ADRs Climb Higher in Wednesday Trading
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
08/15/2022 08/16/2022 08/17/2022 08/18/2022 08/19/2022 Date
5.165(c) 5.14(c) 5.075(c) 4.908(c) 4.926 Last
134 068 148 411 106 521 156 427 12 474 Volume
+3.51% -0.48% -1.26% -3.29% +0.37% Change
More quotes
Estimated financial data (e)
Sales 2022 7,16 M 7,26 M 7,26 M
Net income 2022 -90,9 M -92,2 M -92,2 M
Net cash position 2022 212 M 215 M 215 M
P/E ratio 2022 -5,91x
Yield 2022 -
Sales 2023 11,7 M 11,9 M 11,9 M
Net income 2023 -96,3 M -97,6 M -97,6 M
Net cash position 2023 109 M 111 M 111 M
P/E ratio 2023 -4,48x
Yield 2023 -
Capitalization 461 M 467 M 467 M
EV / Sales 2022 34,8x
EV / Sales 2023 30,0x
Nbr of Employees 87
Free-Float 91,6%
More Financials
Company
DBV Technologies specializes in developing solutions for diagnosing and treating food allergies (primarily to peanuts and cow's milk) using a patch (Viaskin®) that administers active ingredients into the top layers of the skin. 
Sector
Pharmaceuticals
Calendar
08/30Presentation
More about the company
Ratings of DBV Technologies
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about DBV TECHNOLOGIES
08/18European ADRs Move Lower in Thursday Trading
MT
08/12European ADRs Move Slightly Lower in Friday Trading
MT
08/10European ADRs Climb Higher in Wednesday Trading
MT
08/03Kepler Cheuvreux Upgrades DBV Technologies to Buy From Hold
MT
08/02European ADRs Move Lower in Tuesday Trading
MT
08/01DBV TECHNOLOGIES : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
08/01DBV TECHNOLOGIES S.A. Management's Discussion and Analysis of Financial Condition and ..
AQ
08/01DBV Technologies Reports Second Quarter 2022 Financial Results
GL
08/01DBV Technologies Reports Second Quarter 2022 Financial Results
GL
08/01DBV Technologies S.A. Reports Earnings Results for the Second Quarter and Six Months En..
CI
08/01European ADRs Move Higher in Monday Trading
MT
08/01DBV TECHNOLOGIES : Half-year results
CO
07/27Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
GL
07/25European ADRs Move Higher in Monday Trading
MT
07/20European ADRs Move Lower in Wednesday Trading
MT
More news
News in other languages on DBV TECHNOLOGIES
08/18Les ADR européens sont en baisse jeudi
08/12Les ADR européens évoluent en légère baisse dans la négociation de vendredi
08/10Les ADR européens montent en flèche dans les échanges de mercredi
08/02Les ADR européens sont en baisse dans les échanges de mardi
08/02DBV TECHNOLOGIES : perte nette réduite au 2e trimestre
More news
Analyst Recommendations on DBV TECHNOLOGIES
More recommendations
Chart DBV TECHNOLOGIES
Duration : Period :
DBV Technologies Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DBV TECHNOLOGIES
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 4,91 €
Average target price 5,75 €
Spread / Average Target 17,2%
EPS Revisions
Managers and Directors
Daniel Tassé Chief Executive Officer & Executive Director
Sébastien Robitaille Chief Financial Officer
Michel de Rosen Non-Executive Chairman
Pharis Mohideen Chief Medical Officer
Pascal Wotling Chief Technical Operations Officer
Sector and Competitors
1st jan.Capi. (M$)
DBV TECHNOLOGIES60.44%467
MERCK KGAA-19.82%80 212
KYOWA KIRIN CO. LTD.2.07%12 492
SK BIOPHARMACEUTICALS CO., LTD.-19.75%4 606
BETTA PHARMACEUTICALS CO., LTD.-38.96%2 983
YUHAN CORPORATION-8.53%2 919